Status:
COMPLETED
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
Lead Sponsor:
AbbVie
Conditions:
Healthy Volunteers
Generalized Anxiety Disorder (GAD)
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Ge...
Eligibility Criteria
Inclusion
- For healthy volunteer cohort:
- \-- Body mass index (BMI) is \>= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal.
- For participants with generalized anxiety disorder (GAD) or bipolar disorder (BPD)
- Participants with GAD or BPD (as confirmed by MINI) meet participant psychiatric history criteria described in the protocol.
Exclusion
- \- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
Key Trial Info
Start Date :
August 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 4 2025
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT06024239
Start Date
August 31 2023
End Date
March 4 2025
Last Update
March 17 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Collaborative Neuroscience Research CNS /ID# 260270
Los Alamitos, California, United States, 90720
2
Acpru /Id# 255945
Grayslake, Illinois, United States, 60030
3
Hassman Research Institute Marlton Site /ID# 260271
Marlton, New Jersey, United States, 08053